Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope

Immunopharmacology and Immunotoxicology

Volumn 36, Issue 5, 2014, Pages 309-315

  Navari, Mohsen ^a   Zare, Mehrak ^a   Javanmardi, Masoud ^a   Asadi Ghalehni, Majid ^a   Modjtahedi, Helmout ^b   Rasaee, Mohammad Javed ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Cancer vaccine; EGFR; Immunotherapy; Mimotope; Phage display

Indexed keywords

BOVINE SERUM ALBUMIN; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ICR 61; ICR 62; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; PEPTIDE LIBRARY;

ACTIVE IMMUNIZATION; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOASSAY; IN VITRO STUDY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RABBIT; SQUAMOUS CELL CARCINOMA; VACCINATION; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; PEPTIDE LIBRARY; TUMOR CELL LINE;

BOVINAE; ORYCTOLAGUS CUNICULUS; RATTUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; EPITOPE MAPPING; FEMALE; HUMANS; PEPTIDE LIBRARY; RABBITS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERUM ALBUMIN, BOVINE; VACCINATION;

EID: 84925150656     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2014.945127     Document Type: Article

References (38)

1. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol 2013;31:1904-1911.
2. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-334.
3. Crockford A, Jamal-Hanjani M, Hicks J, Swanton C. Implications of intratumour heterogeneity for treatment stratification. J Pathol 2014;232:264-273.
4. Jamal-Hanjani M, Thanopoulou E, Peggs KS, et al. Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol 2013;13:497-503.
5. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
6. Hirsch F, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009;28:S32-S37.
7. Rimawi MF, Shetty PB, Weiss HL, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010;116:1234-1242.
8. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009;20:851-855.
9. Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H. Prognostic significance and targeting of HER family in colorectal cancer. Front Biosci 2012;18:394-421.
10. Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 2010;277:309-315.
11. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-2616.
12. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29(Suppl. 4):47-50.
13. Graeven U, Kremer B, Sudhoff T, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006;94:1293-1299.
14. Modjtahedi H, Styles JM, Dean CJ. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 1993;67:247-253.
15. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. New Engl J Med 2004;351:317-319.
16. Hoyle M, Peters J, Crathorne L, et al. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health 2013;16:288-296.
17. Kanaly CW, Ding D, Heimberger AB, Sampson JH. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am 2010;21:95-109.
18. Riemer AB, Jensen-Jarolim E. Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett 2007;113:1-5.
19. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination-from allergy to cancer. Expert Opin Biol Ther 2009;9:493-506.
20. Castellanos-Serra LR, Fernandez-Patron C, Hardy E, et al. High yield elution of proteins from sodium dodecyl sulfate-polyacrylamide gels at the low-picomole level. Application to N-terminal sequencing of a scarce protein and to in-solution biological activity analysis of on-gel renatured proteins. J Protein Chem 1997;16:415-419.
21. Oliver MH, Harrison NK, Bishop JE, et al. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci 1989;92:513-518.
22. Pandey JP, Kistner-Griffin E, Black L, et al. IGKC and FcγR genotypes and humoral Immunity to HER2 in breast cancer. Immunobiology 2014;219:113-117.
23. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 2012;366:2455-2465.
24. Damiano JS, Rendahl KG, Karim C, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther 2013;12:295-305.
25. Ferraro DA, Gaborit N, Maron R, et al. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci 2013;110:1815-1820.
26. Zappasodi R, Filipazzi P, Rivoltini L, Nicola M. Cancer vaccines and active immunotherapy. In: Younes A, Carbone A, eds. Non-Hodgkin lymphomas: advanced diagnostics & personalized therapies. London: Future Medicine UK; 2013:164-180.
27. Milani A, Sangiolo D, Montemurro F, et al. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 2013;24:1740-1748.
28. Yasser E-M, Honavar V. Recent advances in B-cell epitope prediction methods. Immunome Res 2010;6(Suppl. 2):S2.
29. Witsch EJ, Mahlknecht G, Wakim J, et al. Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int Immunol 2011;23:391-403.
30. Batonick M, Loeffen W, Metwally SA, Mayr GA. Identification and characterization of mimotopes of classical swine fever virus E2 glycoprotein using specific anti-E2 monoclonal antibodies. Virus Res 2013;175:12-19.
31. Hardy B, Raiter A. A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody. Vaccine 2005;23:4283-4291.
32. Cwirla SE, Peters EA, Barrett RW, Dower WJ. Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci 1990;87:6378-6382.
33. Modjtahedi H, Moscatello DK, Box G, et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 2003;105:273-280.
34. Riemer AB, Klinger M, Wagner S, et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004;173:394-401.
35. Hartmann C, Müller N, Blaukat A, et al. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010;29:4517-4527.
36. Wagner S, Hafner C, Allwardt D, et al. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 2005;174:976-982.
37. Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005;97:1663-1670.
38. Foy KC, Wygle RM, Miller MJ, et al. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol 2013;191:217-227.